Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) Interest Expenses (2020 - 2022)

Vivos Therapeutics' Interest Expenses history spans 3 years, with the latest figure at $36000.0 for Q3 2022.

  • Quarterly results put Interest Expenses at $36000.0 for Q3 2022, up 300.0% from a year ago — trailing twelve months through Jun 2023 was $36000.0 (down 59.09% YoY), and the annual figure for FY2021 was $14000.0, down 85.42%.
  • Interest Expenses for Q3 2022 was $36000.0 at Vivos Therapeutics, down from $37000.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $43723.0 in Q1 2020 to a low of $1000.0 in Q1 2021.
  • The 3-year median for Interest Expenses is $17218.0 (2020), against an average of $20181.8.
  • The sharpest move saw Interest Expenses crashed 97.71% in 2021, then surged 3700.0% in 2022.
  • Year by year, Interest Expenses stood at $17218.0 in 2020, then crashed by 76.77% to $4000.0 in 2021, then soared by 800.0% to $36000.0 in 2022.
  • According to Business Quant data, Interest Expenses over the past three periods came in at $36000.0, $37000.0, and $38000.0 for Q3 2022, Q2 2022, and Q1 2022 respectively.